Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth

Journal of Controlled Release

Volumn 159, Issue 3, 2012, Pages 384-392

  Rahman, Mohammad Aminur ^a   Amin, A R M Ruhul ^a   Wang, Xu ^a   Zuckerman, Jonathan E ^b   Choi, Chung Hang J ^b   Zhou, Bingsen ^c   Wang, Dongsheng ^a   Nannapaneni, Sreenivas ^a   Koenig, Lydia ^a   Chen, Zhengjia ^d   Chen, Zhuo Georgia ^a   Yen, Yun ^c   Davis, Mark E ^b   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b California Institute of Technology   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

RNA interference; RRM2; SiRNA delivery; Targeted nanoparticle; TfR; Tumor growth

Indexed keywords

RNA INTERFERENCE; RRM2; SIRNA DELIVERY; TARGETED NANOPARTICLE; TFR; TUMOR GROWTH;

CELL CULTURE; CELL DEATH; CELL PROLIFERATION; ENZYME INHIBITION; NANOPARTICLES; RNA; TUMORS;

GENE THERAPY;

ANTINEOPLASTIC AGENT; CALAA 01; CYCLODEXTRIN; NANOPARTICLE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M2; SMALL INTERFERING RNA NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NANOPARTICLES; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862799430     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.01.045     Document Type: Article

References (37)

1. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
2. D. Bumcrot, M. Manoharan, V. Koteliansky, and D.W. Sah RNAi therapeutics: a potential new class of pharmaceutical drugs Nat. Chem. Biol. 2 2006 711 719
3. D. Castanotto, and J.J. Rossi The promises and pitfalls of RNA-interference-based therapeutics Nature 457 2009 426 433
4. F. Takeshita, and T. Ochiya Therapeutic potential of RNA interference against cancer Cancer Sci. 97 2006 689 696
5. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
6. D.W. Bartlett, and M.E. Davis Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles Bioconjug. Chem. 18 2007 456 468
7. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, and A. Ribas Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
8. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
9. Y. Engstrom, S. Eriksson, I. Jildevik, S. Skog, L. Thelander, and B. Tribukait Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits J. Biol. Chem. 260 1985 9114 9116
10. S. Eriksson, and D.W. Martin Jr. Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2 J. Biol. Chem. 256 1981 9436 9440
11. N.M. Cerqueira, S. Pereira, P.A. Fernandes, and M.J. Ramos Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy Curr. Med. Chem. 12 2005 1283 1294
12. M.S. Duxbury, H. Ito, M.J. Zinner, S.W. Ashley, and E.E. Whang RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine Oncogene 23 2004 1539 1548
13. M.S. Duxbury, H. Ito, E. Benoit, M.J. Zinner, S.W. Ashley, and E.E. Whang Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in pancreatic cancer Surgery 136 2004 261 269
14. Y.W. Zhang, T.L. Jones, S.E. Martin, N.J. Caplen, and Y. Pommier Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response J. Biol. Chem. 284 2009 18085 18095
15. E. Furuta, H. Okuda, A. Kobayashi, and K. Watabe Metabolic genes in cancer: their roles in tumor progression and clinical implications Biochim. Biophys. Acta 1805 2010 141 152
16. B.S. Zhou, P. Tsai, R. Ker, J. Tsai, R. Ho, J. Yu, J. Shih, and Y. Yen Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential Clin. Exp. Metastasis 16 1998 43 49
17. K. Zhang, S. Hu, J. Wu, L. Chen, J. Lu, X. Wang, X. Liu, B. Zhou, and Y. Yen Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis Mol. Cancer 8 2009 11
18. M.S. Duxbury, and E.E. Whang RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness Biochem. Biophys. Res. Commun. 354 2007 190 196
19. J. Souglakos, I. Boukovinas, M. Taron, P. Mendez, D. Mavroudis, M. Tripaki, D. Hatzidaki, A. Koutsopoulos, E. Stathopoulos, V. Georgoulias, and R. Rosell Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine Br. J. Cancer 98 2008 1710 1715
20. T. Morikawa, D. Maeda, H. Kume, Y. Homma, and M. Fukayama Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer Histopathology 57 2010 885 892
21. M.E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol. Pharm. 6 2009 659 668
22. K.C. Gatter, G. Brown, I.S. Trowbridge, R.E. Woolston, and D.Y. Mason Transferrin receptors in human tissues: their distribution and possible clinical relevance J. Clin. Pathol. 36 1983 539 545
23. H.Q. Mao, K. Roy, V.L. Troung-Le, K.A. Janes, K.Y. Lin, Y. Wang, J.T. August, and K.W. Leong Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency J. Control. Release 70 2001 399 421
24. R. Kircheis, T. Blessing, S. Brunner, L. Wightman, and E. Wagner Tumor targeting with surface-shielded ligand-polycation DNA complexes J. Control. Release 72 2001 165 170
25. P.R. Dash, M.L. Read, K.D. Fisher, K.A. Howard, M. Wolfert, D. Oupicky, V. Subr, J. Strohalm, K. Ulbrich, and L.W. Seymour Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin J. Biol. Chem. 275 2000 3793 3802
26. N.C. Bellocq, S.H. Pun, G.S. Jensen, and M.E. Davis Transferrin- containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery Bioconjug. Chem. 14 2003 1122 1132
27. D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, and M.E. Davis Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 104 2007 15549 15554
28. R. Siegel, E. Ward, O. Brawley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J. Clin. 61 2011 212 236
29. X. Zhang, L. Su, A.A. Pirani, H. Wu, H. Zhang, D.M. Shin, K.M. Gernert, and Z.G. Chen Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis Clin. Exp. Metastasis 23 2006 209 222
30. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
31. J.D. Heidel, Z. Yu, J.Y. Liu, S.M. Rele, Y. Liang, R.K. Zeidan, D.J. Kornbrust, and M.E. Davis Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA Proc. Natl. Acad. Sci. U. S. A. 104 2007 5715 5721
32. A. Juhasz, P. Frankel, C. Cheng, H. Rivera, R. Vishwanath, A. Chiu, K. Margolin, Y. Yen, E.M. Newman, T. Synold, S. Wilczynski, H.J. Lenz, D. Gandara, K.S. Albain, J. Longmate, and J.H. Doroshow Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products J. Clin. Lab. Anal. 17 2003 184 194
33. B.S. Zhou, R. Ker, R. Ho, J. Yu, Y.R. Zhao, J. Shih, and Y. Yen Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells Biochem. Pharmacol. 55 1998 1657 1665
34. J.D. Heidel, J.Y. Liu, Y. Yen, B. Zhou, B.S. Heale, J.J. Rossi, D.W. Bartlett, and M.E. Davis Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo Clin. Cancer Res. 13 2007 2207 2215
35. S. Hu-Lieskovan, J.D. Heidel, D.W. Bartlett, M.E. Davis, and T.J. Triche Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma Cancer Res. 65 2005 8984 8992
36. C.H. Choi, C.A. Alabi, P. Webster, and M.E. Davis Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles Proc. Natl. Acad. Sci. U. S. A. 107 2010 1235 1240
37. D.W. Bartlett, and M.E. Davis Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles Biotechnol. Bioeng. 99 2008 975 985